Narcolepsy Type 1 Clinical Trial
Official title:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of NLS-2 (Mazindol Extended-Release) Tablets in the Treatment of Narcolepsy Type 1
The goal of this clinical trial is to see how NLS-2 (mazindol extended-release) works on symptoms of narcolepsy, including cataplexy and excessive daytime sleepiness. Approximately 48 participants will take part in the study across the United States. The study treatment (NLS-2 or placebo) will be administered for 8 weeks. After this treatment period, the participant may have the option to participate in a separate long-term extension study during which all participants will be treated with NLS-2.
This is a Phase 3, double-blind, placebo-controlled, multicenter, randomized, parallel-group clinical trial. The primary goal of this study is to assess the efficacy and safety of NLS-2 (mazindol extended-release) tablets in treating Narcolepsy Type 1. The trial aims to determine the effects of NLS-2 on the improvement of narcolepsy symptoms, including cataplexy frequency and excessive daytime sleepiness. Participants in this trial will receive either NLS-2 or a placebo for 8 weeks. The treatment assignment will be concealed from both the participant and the investigator throughout the trial (unless there is an urgent medical need). Approximately 48 patients will be enrolled at multiple clinical sites across the United States. Following the completion of the trial, participants may be given the option to enroll in a separate long-term extension trial where all participants will receive NLS-2 treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05983731 -
A Pilot Observational Study to Assess the Ability of Continuous 'Home' EEG to Accurately Diagnose Narcolepsy and Demonstrate Response to Treatment
|
||
| Suspended |
NCT04419792 -
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
|
||
| Completed |
NCT05375890 -
Clinical and Neurophysiological Characteristics of Narcolepsy
|
||
| Not yet recruiting |
NCT06292598 -
Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population
|
||
| Recruiting |
NCT06358950 -
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
|
Phase 2 | |
| Not yet recruiting |
NCT06457945 -
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
|
N/A | |
| Not yet recruiting |
NCT06383806 -
Decreasing Nightmares in Adults With Narcolepsy
|
N/A | |
| Completed |
NCT05687903 -
A Study of TAK-861 in Participants With Narcolepsy Type 1
|
Phase 2 | |
| Recruiting |
NCT05967832 -
Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy
|
N/A | |
| Completed |
NCT05709873 -
Narcolepsy Nightmare Study
|
N/A | |
| Recruiting |
NCT04483310 -
Meditation-Relaxation (MR Therapy) for Sleep Paralysis.
|
N/A | |
| Completed |
NCT04445129 -
Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
|
||
| Completed |
NCT05460052 -
Evaluation of the Effectiveness of a Physical Activity Program on the Severity of Narcolepsy
|
||
| Completed |
NCT05314556 -
Group Psychotherapy in Narcolepsy Type 1
|
N/A | |
| Recruiting |
NCT05816382 -
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06336057 -
Mentalizating in Adults Suffering From Narcolepsy Type 1.
|
||
| Recruiting |
NCT06251063 -
Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence
|
N/A | |
| Completed |
NCT06241911 -
Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Narcolepsy Type 1
|
N/A |